COMMUNIQUÉS West-GlobeNewswire

Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
29/05/2019
MET409, a non-bile acid sustained FXR agonist, showed no change in LDL cholesterol, no pruritis and favorable trends in liver fat reduction SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage [...]
Kiadis Pharma's Extraordinary General Meeting of Shareholders Approves CytoSen Acquisition
29/05/2019
Amsterdam, The Netherlands, May 29, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that at its [...]
ESPERITE (ESP) announces termination of MoU regarding proposed sale of stem cell banking business to PBKM due to lack of agreement on the terms of the sale
29/05/2019
Amsterdam, The Netherlands – 29 May 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today that the Memorandum of Understanding (MoU) between Esperite and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM [...]
Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors
29/05/2019
Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors Daix (France), May 29, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for [...]
Nawal Ouzren et Heinz Maeusli nommés au Conseil d'Administration d'Inventiva
29/05/2019
Nawal Ouzren et Heinz Maeusli nommés au Conseil d'Administration d'Inventiva Daix (France), le 29 mai 2019 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
NeuroSearch to implement reverse share split of all shares at consolidation ratio 20:1
29/05/2019
Company announcement 29 May 2019 At the annual general meeting of NeuroSearch A/S (the " Company ") on Monday 29 April 2019, the shareholders resolved to perform a consolidation of shares in the Company by means of a [...]
Saniona publishes its interim report for the first quarter 2019
29/05/2019
PRESS RELEASE May 29, 2019 Financial highlights Q1 2019 (Q1 2018) Net revenues were SEK 1.7 M (4.3 M) EBIT was SEK -29.1 M (-15.7 M) Net profit/loss was SEK -24.8 M (-13.5) Earnings per share were SEK -1.06 (-0.62) [...]
Biocartis Group NV: Disclosure of transparency notifications
29/05/2019
PRESS RELEASE: REGULATED INFORMATION 29 May 2019, 07:00 CEST Disclosure of transparency notifications Mechelen, Belgium, 29 May 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
29/05/2019
Regulated information Gosselies, Belgium, 29 May 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
29/05/2019
Information réglementée Gosselies, Belgique, le 29 mai 2019, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins médicaux [...]
HEXO Corp. announces acquisition of Securities of Newstrike Brands Ltd.
28/05/2019
TORONTO, May 28, 2019 (GLOBE NEWSWIRE) -- On May 24, 2019, HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE-A: HEXO) and Newstrike Brands Ltd. (“ Newstrike ”) announced that they completed the previously announced [...]
HEXO Corp annonce l’acquisition des titres de Newstrike Brands Ltd.
28/05/2019
TORONTO, 28 mai 2019 (GLOBE NEWSWIRE) -- Le 24 mai 2019, HEXO Corp (« HEXO » ou la « Société ») (TSX: HEXO; NYSE-A: HEXO) et Newstrike Brands Ltd. (« Newstrike ») ont annoncé la conclusion de l’arrangement précédemment [...]
Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors
28/05/2019
SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
R1 to Present at the Jefferies 2019 Healthcare Conference
28/05/2019
CHICAGO, May 28, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced its management team will present [...]
Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
28/05/2019
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will [...]
MediPharm Labs Announces $60 Million Bought Deal Equity Financing
28/05/2019
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, May 28, 2019 (GLOBE NEWSWIRE [...]
Genmab Files Registration Statement in the United States for a Proposed Public Offering of American Depositary Shares (ADSs) and Applies for Listing of the ADSs on Nasdaq
28/05/2019
Company Announcement Genmab has today filed a registration statement with the U.S. Securities and Exchange Commission for the proposed public offering of ADSs and has applied for listing of the ADSs on the Nasdaq Global [...]
miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference
28/05/2019
BOULDER, Colo., May 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, [...]
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
28/05/2019
Rockville, MD, May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]

Pages